Most Liquid NASDAQ Biotechnology Companies

Cash And Equivalents
Cash And EquivalentsEfficiencyMarket RiskExp Return
1TRML Tourmaline Bio
147.76 M
 0.20 
 4.08 
 0.84 
2GPCR Structure Therapeutics American
136.28 M
(0.03)
 4.21 
(0.13)
3FTRE Fortrea Holdings
115.57 M
 0.01 
 5.01 
 0.03 
4APGE Apogee Therapeutics, Common
108.08 M
(0.02)
 3.38 
(0.05)
5GMAB Genmab AS
21.61 B
(0.24)
 1.52 
(0.37)
6AMGN Amgen Inc
11.48 B
(0.13)
 1.68 
(0.22)
7VRTX Vertex Pharmaceuticals
9.77 B
(0.01)
 1.67 
(0.01)
8BNTX BioNTech SE
9.33 B
 0.14 
 3.75 
 0.53 
9MRNA Moderna
8.35 B
(0.22)
 3.52 
(0.76)
10REGN Regeneron Pharmaceuticals
7.02 B
(0.39)
 1.72 
(0.68)
11SNY Sanofi ADR
6.9 B
(0.22)
 1.17 
(0.26)
12GILD Gilead Sciences
6.14 B
 0.18 
 1.41 
 0.26 
13BGNE BeiGene
5.7 B
 0.09 
 2.62 
 0.24 
14BIIB Biogen Inc
4.91 B
(0.28)
 1.32 
(0.37)
15AZN AstraZeneca PLC ADR
4.52 B
(0.24)
 1.50 
(0.36)
16GLPG Galapagos NV ADR
4.43 B
(0.02)
 2.26 
(0.04)
17INCY Incyte
2.72 B
 0.09 
 2.50 
 0.21 
18ARGX argenx NV ADR
2.6 B
 0.15 
 1.99 
 0.30 
19ALNY Alnylam Pharmaceuticals
2.27 B
 0.01 
 2.15 
 0.02 
20UTHR United Therapeutics
2.26 B
 0.05 
 1.69 
 0.09 
The analysis above is based on a 90-day investment horizon and a default level of risk. Use the Portfolio Analyzer to fine-tune all your assumptions. Check your current assumptions here.
Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes. Cash equivalents represent current assets that are easily convertible to cash such as short term bonds, savings account, money market funds, or certificate of deposits (CDs). One of the important consideration companies make when classifying assets as cash equivalent is that investments they report on their balance sheets under current assets should have almost no risk of change in value over the next few months (usually three months).